Maroun Hayek, MD
Hematology & Oncology · Greenville, MSNPI 1922072891
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Incyte Corporation accounts for 61.0% of it on its own, with 38 other manufacturers making up the rest. Reporting peaked in 2023 at $4,250 and has fallen 83.6% since, to $697 in 2025. That places this record below the midpoint for hematology & oncology clinicians in MS, where the typical reported total is $9,632.
Across 116 payments — averaging $56.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$4K
- Beigene USA, Inc.$525
- Novartis$325
- Merck$204
- Gilead$156
- Puma Biotechnology, Inc.$113
- plus $1K from 33 others
What the payments were for
- Consulting fees$3,34351%
- Travel & lodging$1,05716%
- Food & beverage$2,06232%
- Education$641%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 8 | $3,981 |
| Beigene USA, Inc. | 1 | $525 |
| Novartis | 17 | $325 |
| Merck | 10 | $204 |
| Gilead | 3 | $156 |
| Puma Biotechnology, Inc. | 8 | $113 |
| Amgen | 5 | $88 |
| Astellas Pharma US Inc | 4 | $86 |
| Daiichi Sankyo Inc. | 4 | $81 |
| E.r. Squibb & Sons, L.L.C. | 4 | $74 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $68 |
| Pfizer | 4 | $63 |
| Bristol Myers Squibb | 3 | $56 |
| Karyopharm Therapeutics Inc. | 3 | $54 |
| Johnson & Johnson(2 entities) | 3 | $52 |
| AstraZeneca | 3 | $49 |
| Seagen Inc. | 3 | $43 |
| EMD Serono, Inc. | 2 | $38 |
| Sanofi | 2 | $37 |
| Sobi, Inc | 2 | $36 |
| Stemline Therapeutics Inc. | 2 | $34 |
| GSK | 2 | $33 |
| Bayer | 2 | $27 |
| Eisai Inc. | 2 | $27 |
| Mirati Therapeutics, Inc. | 1 | $26 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $26 |
| Myriad Genetic Laboratories, Inc. | 1 | $26 |
| Genmab U.S., Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $21 |
| AbbVie | 1 | $19 |
| AVEO Pharmaceuticals, Inc. | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Exelixis Inc. | 1 | $17 |
| Legend Biotech USA Inc. | 1 | $16 |
| Novocure Inc. | 1 | $15 |
| Clovis Oncology, Inc. | 1 | $14 |
| Caris MPI, Inc. | 1 | $14 |
| Beone Medicines USA, Inc. | 1 | $14 |
| Epizyme, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,526 in reported general payments places this provider in the 35th percentile of 57 hematology & oncology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 102 | $1,391,526 |
| KisqaliRibociclib Succinate | 83 | $1,308,342 |
| CalquenceAcalabrutinib Maleate | 72 | $1,052,215 |
| RevlimidLenalidomide | 51 | $936,699 |
| JakafiRuxolitinib Phosphate | 44 | $749,132 |
| ImbruvicaIbrutinib | 31 | $493,908 |
| Lenalidomide | 30 | $431,227 |
| VenclextaVenetoclax | 23 | $323,691 |
| PomalystPomalidomide | 13 | $281,659 |
| XalkoriCrizotinib | 12 | $247,066 |
| SprycelDasatinib | 11 | $190,753 |
| VerzenioAbemaciclib | 13 | $158,432 |
| PromactaEltrombopag Olamine | 11 | $141,633 |
| XareltoRivaroxaban | 40 | $31,857 |
| EliquisApixaban | 35 | $20,694 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisKisqali, Promacta | $325 | $1,449,97594 claims |
| Astellas Pharma US IncXtandi | $86 | $1,391,526102 claims |
| AstraZenecaCalquence | $49 | $1,052,21572 claims |
| Bristol Myers SquibbRevlimid | $56 | $936,69951 claims |
| Incyte CorporationJakafi | $3,981 | $749,13244 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $26 | $493,90831 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $74 | $472,41224 claims |
| AbbVieVenclexta | $19 | $323,69123 claims |
| PfizerXalkori, Eliquis | $63 | $267,76047 claims |
| Lilly USA, LLCVerzenio, Olanzapine | $21 | $158,90780 claims |
| Johnson & JohnsonXarelto | $52 | $31,85740 claims |
| GSKTrelegy Ellipta | $33 | $7,11511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 57 hematology & oncology providers in Mississippi.
Other hematology & oncology in Greenville
- Solly ChedidPascagoula$1.7M
- Carter MilnerJackson$248K
- Guangzhi QuJackson$59K
- Jennifer EubanksMeridian$44K
- Daniel PattersonPascagoula$36K
- John HeneganJackson$35K
- Pamela TuliGulfport$27K
- Sonia BennSouthaven$26K
- Ronald DelrieMcComb$24K
- Matthew CassellMeridian$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.